Form 4: SpringWorks Therapeutics Chief Commercial Officer Converts Equity Holdings Following Merck KGaA Merger

SpringWorks Therapeutics' Chief Commercial Officer, Bhavesh Ashar, converted all common stock, restricted stock units, performance share units, and stock options into cash or cash-based awards following the company's acquisition by Merck KGaA.

Summary

• SpringWorks Therapeutics, Inc. (SWTX) completed its merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, with SpringWorks Therapeutics becoming a wholly owned subsidiary of Merck KGaA.
• As a result of the merger, each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash.
• Bhavesh Ashar, Chief Commercial Officer, disposed of 62,053 shares of common stock, which included 42,748 shares underlying restricted stock units (RSUs).
• All outstanding restricted stock units (RSUs), whether vested or unvested, were cancelled and converted into cash-based awards, with the cash amount equal to the merger consideration multiplied by the number of shares subject to the RSU.
• Performance Share Units (PSUs) totaling 21,654 units were also cancelled and converted into cash-based awards, calculated based on the merger consideration and the number of shares vesting according to performance levels.
• Stock options, including 100,000 at an exercise price of $26.98, 70,000 at $27.64, 75,000 at $38.40, and 50,615 at $43.00, were cancelled and converted into cash or cash-based awards.
• For in-the-money options, the cash amount was calculated as the number of shares subject to the option multiplied by the excess of the $47.00 merger consideration over the option's exercise price.
• Unvested options were converted into Parent Cash-Based Option Awards, which generally retain their original vesting terms, but 50% of each then-unvested tranche will vest on the nine-month anniversary of the merger closing date, subject to continued employment.

Sentiment

Score: 5

Explanation: The document reports a standard transaction for an executive's equity holdings following a merger. While in-the-money awards converted to cash, out-of-the-money options were cancelled without compensation, balancing the overall sentiment for the reporting person's specific holdings.

Positives

• Shareholders received a cash consideration of $47.00 per share for their common stock.
• In-the-money stock options and equity awards (RSUs, PSUs) were converted into cash or cash-based awards, providing liquidity to holders.
• A portion (50%) of unvested cash-based RSU and option awards will accelerate vesting on the nine-month anniversary of the merger closing date, subject to continued employment.

Negatives

• Any outstanding stock options with an exercise price greater than the $47.00 merger consideration were cancelled for no consideration or payment.

Future Outlook

Unvested cash-based RSU awards and option awards will generally vest according to their original terms, with an accelerated vesting of 50% of each then-unvested tranche on the nine-month anniversary of the merger closing date, contingent on the holder's continued employment.

Industry Context

This filing reflects the finalization of a significant acquisition in the biotechnology sector, where a larger pharmaceutical company (Merck KGaA) has acquired a smaller, publicly traded therapeutics company (SpringWorks Therapeutics). Such mergers are common in the industry for strategic portfolio expansion and pipeline integration.

Stakeholder Impact

• Shareholders received a fixed cash payment for their shares, providing a clear exit value.
• Employees, including the Chief Commercial Officer, had their equity converted into cash or cash-based awards, with some accelerated vesting, contingent on continued employment, impacting their long-term incentive structure and retention.

Next Steps

• Continued employment of the reporting person with the acquiring entity (Merck KGaA) to facilitate the vesting of remaining cash-based equity awards.
• Vesting of 50% of each then-unvested tranche of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards on the nine-month anniversary of the merger closing date.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merger, Acquisition, Merck KGaA, SEC Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Stock Units, Performance Share Units, Change of Control